

# Udo Rudloff

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8204437/publications.pdf>

Version: 2024-02-01

30  
papers

1,252  
citations

471509

17  
h-index

477307

29  
g-index

31  
all docs

31  
docs citations

31  
times ranked

2052  
citing authors

#	ARTICLE	IF	CITATIONS
1	Teaching principles of translational science to a broad scientific audience using a case study approach: A pilot course from the National Center for Advancing Translational Sciences. <i>Journal of Clinical and Translational Science</i> , 2022, 6, .	0.6	4
2	Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8303-8331.	6.4	4
3	Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. <i>Investigational New Drugs</i> , 2021, 39, 821-828.	2.6	24
4	Mini-Review: PDPK1 (3-phosphoinositide dependent protein kinase-1), An Emerging Cancer Stem Cell Target. <i>Journal of Cancer Treatment &amp; Diagnosis</i> , 2021, 5, 30-35.	0.9	4
5	T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGF $\beta$ 2R1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1926-1940.	4.1	9
6	Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. <i>Cancer Discovery</i> , 2020, 10, 104-123.	9.4	131
7	LC-MS/MS assay coupled with carboxylic acid magnetic bead affinity capture to quantitatively measure cationic host defense peptides (HDPs) in complex matrices with application to preclinical pharmacokinetic studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 181, 113093.	2.8	1
8	Metabolism and pharmacokinetics characterization of metarrestin in multiple species. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 805-816.	2.3	6
9	Safety assessment of metarrestin in dogs: A clinical candidate targeting a subnuclear structure unique to metastatic cancer cells. <i>Regulatory Toxicology and Pharmacology</i> , 2020, 116, 104716.	2.7	4
10	Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	205
11	Associations of CDH1 germline variant location and cancer phenotype in families with hereditary diffuse gastric cancer (HDGC). <i>Journal of Medical Genetics</i> , 2019, 56, 370-379.	3.2	33
12	Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cell-Like Phenotype. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2097-2110.	4.1	16
13	The Changing Paradigm of Management of Liver Abscesses in Chronic Granulomatous Disease. <i>Clinical Infectious Diseases</i> , 2018, 66, 1427-1434.	5.8	31
14	Adjuvant intraperitoneal chemotherapy for the treatment of colorectal cancer at risk for peritoneal carcinomatosis: a systematic review. <i>International Journal of Hyperthermia</i> , 2018, 34, 501-511.	2.5	2
15	Gastric adenocarcinoma and proximal polyposis of the stomach: diagnosis and clinical perspectives. <i>Clinical and Experimental Gastroenterology</i> , 2018, Volume 11, 447-459.	2.3	40
16	Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 1067-1080.	2.3	9
17	Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	55
18	Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells. <i>BMC Cancer</i> , 2018, 18, 772.	2.6	17

#	ARTICLE	IF	CITATIONS
19	Merging perspectives: genotype-directed molecular therapy for hereditary diffuse gastric cancer (HDGC) and E-cadherin-EGFR crosstalk. <i>Clinical and Translational Medicine</i> , 2018, 7, 7.	4.0	22
20	Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer. <i>Journal of Translational Medicine</i> , 2017, 15, 92.	4.4	14
21	Adjuvant intraperitoneal chemotherapy for the treatment of gastric cancer at risk for peritoneal carcinomatosis: A systematic review. <i>Journal of Surgical Oncology</i> , 2017, 115, 192-201.	1.7	25
22	Expression of the scaffold connector enhancer of kinase suppressor of Ras 1 (CNKSR1) is correlated with clinical outcome in pancreatic cancer. <i>BMC Cancer</i> , 2017, 17, 495.	2.6	10
23	Liver Label Retaining Cancer Cells Are Relatively Resistant to the Reported Anti-Cancer Stem Cell Drug Metformin. <i>Journal of Cancer</i> , 2016, 7, 1142-1151.	2.5	28
24	Î2-Catenin activation in fundic gland polyps, gastric cancer and colonic polyps in families afflicted by gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS). <i>Journal of Clinical Pathology</i> , 2016, 69, 826-833.	2.0	20
25	Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. <i>American Journal of Human Genetics</i> , 2016, 98, 830-842.	6.2	201
26	Whole Genome Sequencing of Newly Established Pancreatic Cancer Lines Identifies Novel Somatic Mutation (c.2587G>A) in Axon Guidance Receptor Plexin A1 as Enhancer of Proliferation and Invasion. <i>PLoS ONE</i> , 2016, 11, e0149833.	2.5	21
27	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer and other less common disease histologies: is it time?. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 87-98.	1.4	18
28	Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial. <i>Journal of Surgical Oncology</i> , 2014, 110, 275-284.	1.7	159
29	Label-retaining liver cancer cells are relatively resistant to sorafenib. <i>Gut</i> , 2013, 62, 1777-1786.	12.1	91
30	A growing family: Adding mutated Erbb4 as a novel cancer target. <i>Cell Cycle</i> , 2010, 9, 1487-1503.	2.6	34